Viva Biotech Holdings (1873.HK)

0.590 +0.010 (+1.72%) At close: 04:08PM HKT

Viva Biotech Holdings

No.735, Ziping Road
Zhoupu Town Pudong New District
Shanghai 201318
China
86 21 6089 3288
https://www.vivabiotech.com.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,077

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Chen Cheney Mao Ph.D.	Chairman & CEO	1.85M	N/A	1962
Mr. Ying Wu M.B.A.	Executive VP & Executive Director	1.5M	N/A	1963
Dr. Delin Ren Ph.D.	Executive Director	2.61M	N/A	1961
Mr. Zheren Wang C.F.A.	Co-Chief Financial Officer	N/A	N/A	1984
Mr. Wei Xiong	Co-Chief Financial Officer	N/A	N/A	1984
Mr. Xueheng Cheng Ph.D.	Chief Technology Officer	N/A	N/A	1956
Dr. Zhixiong Ye Ph.D.	Chief Scientific Officer	N/A	N/A	1960
Mr. Han Dai Ph.D.	Chief Innovation Officer & Head of Viva BioInnovator	N/A	N/A	1980
Mr. Jianhua Cai Ph.D.	Senior Vice President	N/A	N/A	N/A
Jianguo Ma Ph.D.	Senior VP & CEO of Langhua Pharmaceutical	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides laboratory rental, and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.

Corporate governance

Viva Biotech Holdings’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.